described \u0430\u043d\u0442\u0438\u0433\u0435\u043d\u0441\u0432\u044f\u0437\u044b\u0432\u0430\u044e\u0449\u0438\u0435 proteins with TCR like \u043f\u0430\u0440\u0430\u0442\u043e\u043f\u0430\u043c\u0438). with the \u0430\u043d\u0442\u0438\u0433\u0435\u043d\u0441\u0432\u044f\u0437\u044b\u0432\u0430\u044e\u0449\u0435\u0439 area specific for hla - a2 - \u0440\u0435\u0441\u0442\u0440\u0438\u043a\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u043c\u0443 \u043f\u0435\u043f\u0442\u0438\u0434\u0443. \u0430\u043d\u0442\u0438\u0433\u0435\u043d\u0441\u0432\u044f\u0437\u044b\u0432\u0430\u044e\u0449\u0438\u0435 proteins include antibodies in various forms, including all full-size antibodies, mainly \u0438\u043d\u0442\u0430\u043a\u0442\u043d\u044b\u0435 antibodies, fab fragments, f (ab ) fragments and one \u0446\u0435\u043f\u043e\u0447\u0435\u0447\u043d\u044b\u0435 Fv fragments.the invention also deals with the hybrid proteins, such as hybrids scFv with substances or with t - \u043a\u043b\u0435\u0442\u043e\u0447\u043d\u044b\u043c\u0438 \u0440\u0435\u0446\u0435\u043f\u0442\u043e\u0440\u043d\u044b\u043c\u0438 domains, including \u0430\u043d\u0442\u0438\u0433\u0435\u043d\u0441\u0432\u044f\u0437\u044b\u0432 \u0430\u044e\u0449\u0443\u044e area, specific to each \u043f\u0435\u043f\u0442\u0438\u0434\u0443.in addition, the invention also considers the \u0438\u043c\u043c\u0443\u043d\u043e\u043a\u043e\u043d\u044a\u044e\u0433\u0430\u0442\u044b, which may include antibodies associated with \u0440\u0430\u0434\u0438\u043e\u0438\u0437\u043e\u0442\u043e\u043f\u043e\u043c, fluorescent marker or other \u0434\u0435\u0442\u0435\u043a\u0442\u0438\u0440\u0443\u0435\u043c\u044b\u043c marker with \u0446\u0438\u0442\u043e\u0442\u043e\u043a\u0441\u0438\u043d\u043e\u043c or other molecules. in addition, \u0438\u043c\u043c\u0443\u043d\u043e\u043a\u043e\u043d\u044a\u044e\u0433\u0430\u0442 can be used for delivery of an agent required to generate therapeutic effect, or to improve the immune efficiency
